Malone Margaret
Department of Pharmacy Practice, Albany College of Pharmacy, New York 12208, USA.
JPEN J Parenter Enteral Nutr. 2002 May-Jun;26(3):164-8. doi: 10.1177/0148607102026003164.
The purpose of this study was to assess the health status, frequency of therapy-related symptoms, and impact of home parenteral and enteral nutrition (HPEN) on lifestyle in patients who were stable and had nonmalignant diagnoses. Assessments were made at 2 time points, 3 years apart.
Institutional review board approval was obtained. Adult HPEN patients self-completed a general health status questionnaire (SF-36) and a lifestyle-symptom questionnaire in 1993 and 1996. Demographic data relating to underlying disease state and infusion regimen were also collected.
Seventeen patients (7 men, 10 women; 13 receiving home parenteral nutrition [HPN] and 4 receiving home enteral nutrition [HEN]) participated in the study. The mean (SEM) duration of HPEN therapy at the start of the study was 7.1 (1.6) years. Although health status as assessed by SF-36 scores was lower in all categories when compared with age- and gender-matched control data from the general US population (p < .05), there was no significant difference in SF-36 scores between the 2 time periods (p > .05). Sleep, travel, and social activities were the most affected aspects of the patient's lifestyle.
These data suggest that patients with nonmalignant underlying disease receiving HPEN maintain a stable health status over a prolonged period.
本研究旨在评估病情稳定且诊断为非恶性疾病的患者的健康状况、治疗相关症状的发生频率以及家庭肠外和肠内营养(HPEN)对其生活方式的影响。评估在两个时间点进行,间隔3年。
获得了机构审查委员会的批准。1993年和1996年,成年HPEN患者自行填写了一份一般健康状况问卷(SF - 36)和一份生活方式 - 症状问卷。还收集了与基础疾病状态和输注方案相关的人口统计学数据。
17名患者(7名男性,10名女性;13名接受家庭肠外营养[HPN],4名接受家庭肠内营养[HEN])参与了研究。研究开始时HPEN治疗的平均(SEM)持续时间为7.1(1.6)年。尽管与来自美国普通人群的年龄和性别匹配的对照数据相比,SF - 36评分评估的所有类别中的健康状况都较低(p < 0.05),但两个时间段之间的SF - 36评分没有显著差异(p > 0.05)。睡眠、旅行和社交活动是患者生活方式中受影响最大的方面。
这些数据表明,接受HPEN的非恶性基础疾病患者在较长时间内保持稳定的健康状况。